Yann Abraham
Affiliations: | Université Paris-Sud 11, Orsay, Bures-sur-Yvette, Île-de-France, France |
Google:
"Yann Abraham"Parents
Sign in to add mentor| Michel Bornens | grad student | 2001 | Université Paris-Sud 11 | |
| (Duplication du centrosome, recherche de partenaires de la protéine HsCen3p) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Casneuf T, Adams HC, van de Donk NWCJ, et al. (2020) Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. Leukemia |
| Philippar U, Lu T, Vloemans N, et al. (2020) Abstract 5690: Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas Cancer Research. 80: 5690-5690 |
| Philippar U, Lu T, Vloemans N, et al. (2019) Discovery Of A Novel, Potential First‐In‐Class Malt1 Protease Inhibitor For The Treatment Of B Cell Lymphomas Hematological Oncology. 37: 128-128 |
| Adams HC, Stevenaert F, Krejcik J, et al. (2018) High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. Cytometry. Part a : the Journal of the International Society For Analytical Cytology |
| Brady LK, Soong D, Lind EF, et al. (2018) Immunogenomic Exploration of the Acute Myeloid Leukemia Microenvironment Identifies Determinants of T-Cell Fitness Blood. 132: 2750-2750 |
| Donk NWVD, Adams H, Vanhoof G, et al. (2017) Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-Cells in Pollux, a Phase 3 Randomized Study Blood. 130: 3124-3124 |
| Abraham Y, Gerrits B, Ludwig MG, et al. (2016) Exploring Glucocorticoid Receptor Agonists Mechanism of Action through Mass Cytometry and Radial Visualizations. Cytometry. Part B, Clinical Cytometry |
| Adams H, Stevenaert F, Krejcik J, et al. (2016) High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action Blood. 128: 4521-4521 |
| Agarinis C, Orsini V, Megel P, et al. (2015) Activation of Yap-Directed Transcription by Knockdown of Conserved Cellular Functions. Journal of Biomolecular Screening |
| Marti P, Stein C, Blumer T, et al. (2015) YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors. Hepatology (Baltimore, Md.). 62: 1497-510 |